Corbus Pharmaceuticals Holdings Inc (CRBP) FinancialsCRBPCorbus Pharmaceuticals Holdings Inc

Evaluating the bottom line, Corbus Pharmaceuticals Holdings, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -95.58%, provide a clear picture of how effectively CRBP converts its operational activities into shareholder value.

In the context of the broader market, CRBP competes directly with industry leaders such as ABOS and DERM. With a market capitalization of $218.17M, it holds a significant position in the sector. When comparing efficiency, CRBP's gross margin of N/A stands against ABOS's N/A and DERM's 61.58%. Such benchmarking helps identify whether Corbus Pharmaceuticals Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Corbus Pharmaceuticals has a current ratio of 5.71, indicating good liquidity, but it has reported consistent net losses, with the latest quarterly net income at -35,037,000 USD.